NASDAQ · AKBA
Healthcare · Biotechnology
$0.95
Down-$0.01 (-0.78%)
Updated Sep 11, 2026, 1:50 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
AKBA closed at $0.95 after 19 trading sessions, up 9.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.03 | $1.049 | $0.95 | $0.9539 | 4.88M |
| Sep 8, 2026 | $0.9616 | $1.03 | $0.9528 | $1.03 | 3.06M |
| Sep 4, 2026 | $0.988 | $0.9961 | $0.9471 | $0.9747 | 8.35M |
| Sep 3, 2026 | $0.9999 | $1.00 | $0.9615 | $0.9833 | 7.46M |
| Sep 2, 2026 | $0.95 | $1.01 | $0.9474 | $0.9803 | 12.86M |
| Sep 1, 2026 | $0.9099 | $0.9472 | $0.9099 | $0.9447 | 12.45M |
| Aug 31, 2026 | $0.88 | $0.9349 | $0.855 | $0.9188 | 15.18M |
| Aug 28, 2026 | $0.935 | $0.94 | $0.865 | $0.8786 | 10.19M |
| Aug 27, 2026 | $0.91 | $0.96 | $0.9056 | $0.9398 | 13.29M |
| Aug 26, 2026 | $0.957 | $0.957 | $0.8762 | $0.9065 | 14.03M |
| Aug 25, 2026 | $0.90 | $0.963 | $0.90 | $0.9584 | 11.34M |
| Aug 24, 2026 | $0.9078 | $0.9106 | $0.8723 | $0.9006 | 8.13M |
| Aug 21, 2026 | $0.9249 | $0.955 | $0.9055 | $0.9066 | 6.45M |
| Aug 20, 2026 | $0.88 | $0.9298 | $0.8722 | $0.9194 | 13.72M |
| Aug 19, 2026 | $0.8518 | $0.8977 | $0.85 | $0.8854 | 9.88M |
| Aug 18, 2026 | $0.8569 | $0.8626 | $0.8382 | $0.8518 | 1.96M |
| Aug 17, 2026 | $0.87 | $0.88 | $0.814 | $0.86 | 4.26M |
| Aug 14, 2026 | $0.87 | $0.8882 | $0.8581 | $0.8728 | 2.09M |
| Aug 13, 2026 | $0.9046 | $0.949 | $0.8641 | $0.8696 | 4.09M |
The latest Smart Investors Daily articles mentioning AKBA.
AKBA research
Company profile and research snapshot.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | WestPark Capital | Buy | — |
| Aug 7, 2026 | Leerink Partners | Market Perform | — |
| Jul 1, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2026 | BTIG | Buy | — |
| Feb 25, 2026 | BTIG | Buy | — |
Generated Sep 10, 2026, 9:02 PM
Akebia Therapeutics (AKBA) declined modestly by 0.78% today despite receiving a new positive analyst endorsement. WestPark Capital initiated coverage on the biopharmaceutical company with a Buy rating and $4.5 price target, suggesting the market may already be pricing in positive sentiment or investors are adopting a 'sell the news' approach.
Bottom line: WestPark Capital's Buy initiation provides a positive fundamental backdrop for AKBA, but today's modest decline suggests the market is taking a cautious wait-and-see approach. Investors should monitor upcoming clinical trial results and regulatory developments as key catalysts that could validate the analyst's bullish thesis and drive meaningful upside toward the $4.5 target.
Benzinga · Sep 8, 2026
WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.
Yahoo · Sep 1, 2026
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(
Yahoo · Sep 1, 2026
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026. During meetings, management will disc
Benzinga · Aug 7, 2026
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AKBA.
